循環器ジャーナル67巻3号

2019年07月発行

特集 循環器疾患の画像診断—現状と進歩 Ⅲ．心筋症

MRIでどこまで診断できるか

著者： 橋村宏美¹ 植田初江²

所属機関： ¹西宮渡辺心臓脳・血管センター放射線科 ²国立循環器病研究センター病理部

ページ範囲：P.378 - P.387

Point
・心臓MRIでは，様々な撮像シークエンスを利用して，形態評価（冠動脈・心室壁厚），心機能解析，血流評価，心筋還流，心筋性状を評価できる．
・心筋症の診断には，cine MRIによる形態評価・心収縮能評価と遅延造影による障害心筋の評価が重要となる．
・本稿では，特に日常臨床で遭遇する肥大型心筋症・拡張型心筋症・不整脈原性右室心筋症・心臓サルコイドーシス・心アミロイドーシスについて，心臓MRI遅延造影と，最近心筋性状の新たな評価方法として注目されているT1 mapping，これらを理解するために必要な病理組織学的所見を示す．

参考文献

1) Liu S, Han J, Nacif MS, et al:Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping:sample size considerations for clinical trials. J Cardiovasc Magn Reson 14:90, 2012

2) Kawel N, Nacif M, Zavodni A, et al:T1 mapping of the myocardium:intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region. J Cardiovasc Magn Reson 14:27, 2012

3) Marian AJ, Roberts R:The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 33:655-670, 2001

4) Fujiwara H, Fujiwara T, Hamashima Y, et al:Number and size of myocytes, amount of interstitial space and extent of disarray of the hearts in patients with systemic hypertension and asymmetric septal hypertrophy. Jpn Circ J 49:406-414, 1985

5) Hashimura H, Kimura F, Ishibashi-Ueda H, et al:Radiologic-Pathologic Correlation of Primary and Secondary Cardiomyopathies:MR Imaging and Histopathologic Findings in Hearts from Autopsy and Transplantation. Radiographics 37:719-736, 2017

6) Puntmann VO, Voigt T, Chen Z, et al:Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 6:475-484, 2013

7) Maron BJ, Towbin JA, Thiene G, et al:Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee;Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups;and Council on Epidemiology and Prevention. Circulation 113:1807-1816, 2006

8) Sheppard MN, Davies MJ:Dilated cardiomyopathy（DCM）. In:Practical Cardiovascular Pathology, 2nd ed. Hodder Arnold, London, 151-154, 2011

9) McCrohon JA, Moon JC, Prasad SK, et al:Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108:54-59, 2003

10) Marcus FI, McKenna WJ, Sherrill D, et al:Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia:proposed modification of the Task Force Criteria. Eur Heart J 31:806-814, 2010

11) Norman M, Simpson M, Mogensen J, et al:Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation 112:636-642, 2005

12) te Riele AS, Tandri H, Bluemke DA:Arrhythmogenic right ventricular cardiomyopathy（ARVC）:cardiovascular magnetic resonance update. J Cardiovasc Magn Reson16:50, 2014

13) Burke A, Tavora F:Arrhythmogenic cardiomyopathy（arrhythmogenic right ventricular dysplasia/cardiomyopathy）. In:Pine MJ ed. Practical Cardiovascular Pathology. Wolters Kluwer Health/ Lippincott Williams ＆ Wilkins, Philadelphia, pp169-177, 2011

14) Sheppard MN, Davies MJ, Arrhythmogenic right ventricular cardiomyopathy, in Practical cardiovascular pathology, 2nd ed. Hodder Arnold, London, pp168-173, 2011

15) Burke AP, Farb A, Tashko G, et al:Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium:are they different diseases? Circulation 97:1571-1580, 1998

16) Marra MP, Leoni L, Bauce B, et al:Imaging study of ventricular scar in arrhythmogenic right ventricular cardiomyopathy:comparison of 3D standard electroanatomical voltage mapping and contrast-enhanced cardiac magnetic resonance. Circ Arrhythm Electrophysiol 5:91-100, 2012

17) Tandri H, Saranathan M, Rodriguez ER, et al:Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 45:98-103, 2005

18) 日本循環器学会：2016年版心臓サルコイドーシスの診断ガイドライン．2016

19) Ardehali H, Howard DL, Hariri A, et al:A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 150:459-463, 2005

20) Ohira H, Tsujino I, Ishimaru S, et al:Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 35:933-941, 2008

21) Falk RH:Diagnosis and management of the cardiac amyloidoses. Circulation 112:2047-2060, 2005

22) Burke A, Tavora F:Restrictive cardiomyopathy and cardiac amyloidosis. In:Pine JW, ed. Practical Cardiovascular Pathology. Wolters Kluwer Health/ Lippincott Williams ＆ Wilkins, Philadelphia, pp184-194, 2011

23) Nam BD, Kim SM, Jung HN, et al:Comparison of quantitative imaging parameters using cardiovascular magnetic resonance between cardiac amyloidosis and hypertrophic cardiomyopathy:inversion time scout versus T1 mapping. Int J Cardiovasc Imaging 34:1769-1777, 2018